[A novel method for sentinel lymph node mapping using magnetite].

Yoshihiro Minamiya; Jun-ichi Ogawa

Home/Archive/PubMed

PubMed · 14628710

[A novel method for sentinel lymph node mapping using magnetite].

Yoshihiro Minamiya·Jun-ichi Ogawa

View original source ↗Export metadata ↓

Abstract

The detection rate of sentinel lymph nodes using isosulfan blue dye is too low for clinical use. Although exposure to radioactivity is reportedly minimal, special procedures are nonetheless required when a radioactive isotope is used as a tracer. Therefore, to eliminate the need for a radioactive tracer and to obtain a better detection rate than is currently obtained with isosulfan blue dye, we have developed a novel method that employs magnetite as the tracer. The tracer employed is ferumoxides, a colloidal superparamagnetic iron oxide of non-stoichiometric magnetite. The magnetic force within the lymph nodes was measured using a highly sensitive hand-held magnetometer ex vivo. The rate of detection of sentinel lymph nodes was 82% in non-small cell lung cancer. Intraoperative sentinel lymph node mapping using ferumoxides and a highly sensitive magnetometer is a safe, accurate, and sensitive way to detect sentinel lymph nodes. To detect sentinel lymph nodes in vivo, the magnetometer should be sterilized and the sensitivity of the magnetometer should be higher than that we used. Therefore now we are developing a more sensitive and sterilizable magnetometer.

Explore related subjects

Contrast Media Dextrans Ferrosoferric Oxide Humans Iron Magnetics Magnetite Nanoparticles Oxides Sensitivity and Specificity Sentinel Lymph Node Biopsy Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Yoshihiro Minamiya, Jun-ichi Ogawa. 2003. [A novel method for sentinel lymph node mapping using magnetite].. https://pubmed.ncbi.nlm.nih.gov/14628710/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Type, severity, frequency and management of adverse reactions associated with ultrasound contrast agents: a systematic review and meta-analysis.

OBJECTIVES: This systematic review and meta-analysis are aimed at evaluating the incidence of adverse drug reactions (ADRs) following administration of clinically approved ultrasound contrast agents (UCAs) in adults and children, to assess risks in patients with cardiovascular disease and in pregnancy, and to evaluate the effectiveness of emergency management of severe ADRs. MATERIALS AND METHODS: A PRISMA 2020 systematic review was conducted searching PubMed, Scopus, and Embase. Two reviewers independently screened, extracted data, and assessed quality. Incidence estimates were pooled when feasible, stratified by age group, contrast agent, and administration route. RESULTS: Seventy-four studies encompassing > 1 million adults and > 36,000 children were included, contributing multiple analytic cohorts to the quantitative synthesis. Severe acute ADRs were extremely rare (6 and 16 cases per 100,000 in adults and children, respectively) and absent following endocavitary administration in children. Non-severe acute ADRs occurred in 11 and 8 cases per 10,000 adults and children, respectively. Delayed reactions were very rare (< 1 case per million in adults). No significant safety differences emerged between UCA products. The incidence of ADRs in patients with cardiovascular disease was analogous to the general population. No ADRs were reported in pregnant women. Standard emergency management was effective in almost all serious cases, though rare fatalities occurred. CONCLUSION: UCAs show an excellent safety profile in adults and children, with very rare severe ADRs and few non-severe, typically self-limiting reactions. Strict adherence to recommended emergency management protocols mitigates the remaining risks, supporting safe use across a broad range of clinical indications. PROSPERO REGISTRATION: CRD42023432668. KEY POINTS: Question What is the incidence, type, and severity of acute and delayed ADRs associated with clinically approved UCAs across different patient populations? Findings Severe acute adverse reactions are very rare, and non-severe reactions are rare and self-limiting, with no significant safety differences between adults, children, or patients with cardiovascular disease. Clinical relevant UCAs show an excellent safety profile across populations. These findings support their safe clinical use as reliable alternatives to iodine-based and gadolinium-based contrast agents in routine diagnostic imaging.

Contrast Media↗

PubMed2005

When are two waters worse than one? Doubling the hydration number of a Gd-DTPA derivative decreases relaxivity.

The synthesis of a novel ligand, based on N-methyl-diethylenetriaminetetraacetate and containing a diphenylcyclohexyl serum albumin binding group (L1) is described and the coordination chemistry and biophysical properties of its Gd(III) complex Gd-L1 are reported. The Gd(III) complex of the diethylenetriaminepentaacetate analogue of the ligand described here (L2) is the MRI contrast agent MS-325. The effect of converting an acetate to a methyl group on metal-ligand stability, hydration number, water-exchange rate, relaxivity, and binding to the protein human serum albumin (HSA) is explored. The complex Gd-L1 has two coordinated water molecules in solution, that is, [Gd(L1)(H2O)2]2- as shown by D-band proton ENDOR spectroscopy and implied by 1H and 17O NMR relaxation rate measurements. The Gd-H(water) distance of the coordinated waters was found to be identical to that found for Gd-L2, 3.08 A. Loss of the acetate group destabilizes the Gd(III) complex by 1.7 log units (log K(ML) = 20.34) relative to the complex with L2. The affinity of Gd-L1 for HSA is essentially the same as that of Gd-L2. The water-exchange rate of the two coordinated waters on Gd-L1 (k(ex) = 4.4x10(5) s(-1)) is slowed by an order of magnitude relative to Gd-L2. As a result of this slow water-exchange rate, the observed proton relaxivity of Gd-L1 is much lower in a solution of HSA under physiological conditions (r1(obs) = 22.0 mM(-1) s(-1) for 0.1 mM Gd-L1 in 0.67 mM HSA, HEPES buffer, pH 7.4, 35 degrees C at 20 MHz) than that of Gd-L2 (r1(obs) = 41.5 mM(-1) s(-1)) measured under the same conditions. Despite having two exchangeable water molecules, slow water exchange limits the potential efficacy of Gd-L1 as an MRI contrast agent.

Contrast Media↗

PubMed2005

X-rays and radiopaque drugs.

PURPOSE: The generation of x-rays for diagnostic imaging, formation of the radiographic image, and pharmacodynamics of radiopaque drugs are reviewed. SUMMARY: Medical radiographic imaging uses x-rays to obtain an image of a particular structure or function of the human body. Darkening of the radiographic image occurs at points that correspond with the interactions of x-rays. Unlike visible light, x-rays comprise a higher-energy, ionizing portion of the electromagnetic spectrum that is capable of penetrating and ionizing matter, breaking chemical bonds, damaging tissues, and rendering an image of tissue characteristics beneath the surface. The beam of x-rays is directed to a tissue target and emerges encoded with data that initiate image formation with film or a video screen (the receptor complex). Braking radiation and characteristic radiation form the primary beam, which is modified into the image-forming beam through interaction with the target. Radiopaque drugs selectively enhance the emergent data pattern and thereby improve formation of the image. Atomic electron theory is reviewed, and the interaction of x-rays with tissue and radiopaque drugs is discussed in detail. CONCLUSION: Radiopaque drugs can interact with x-rays to improve the visualization of tissues and anatomical structures.

Contrast Media↗